Vertex Pharmaceuticals Incorporated (VRTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Vertex Pharmaceuticals Incorporated (VRTX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (86% profit margin, 20% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How VRTX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | 86.2% | 34.8% | $3.95B | $3.19B | 19.7% |
| FY 2024 | $11.02B | 86.1% | -2.1% | -$535.6M | -$790.3M | -1.3% |
| FY 2023 | $9.87B | 44% | 38.8% | $3.62B | $3.09B | 6.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring VRTX)
- ✓Live walkthrough of VRTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
VRTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VRTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VRTX. Explore sector supply chains on /butterfly.
VRTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Vertex Pharmaceuticals Incorporated (VRTX)?
In FY 2025 (10-K), VRTX converted $12.0B of revenue into a 86.2% gross margin, 34.8% operating margin, and $3.2B in free cash flow (26.6% FCF margin).